IBIO Valuation

iBio Inc

Add to Watchlist

Advanced Chart

0.690

-0.02(-2.817%)1D

Overview
Forecast
Valuation
Earnings

IBIO Relative Valuation

IBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IBIO is overvalued; if below, it's undervalued.

Historical Valuation

iBio Inc (IBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 178.27 is considered Fairly compared with the five-year average of -4.84. The fair price of iBio Inc (IBIO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.69

Fair

-0.76

Trailing

Forward

0.00

EV/EBITDA

iBio Inc. (IBIO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.63

EV/EBIT

iBio Inc. (IBIO) has a current EV/EBIT of -0.63. The 5-year average EV/EBIT is -2.90. The thresholds are as follows: Strongly Undervalued below -10.11, Undervalued between -10.11 and -6.50, Fairly Valued between 0.71 and -6.50, Overvalued between 0.71 and 4.32, and Strongly Overvalued above 4.32. The current Forward EV/EBIT of -0.63 falls within the Historic Trend Line -Fairly Valued range.

178.27

iBio Inc. (IBIO) has a current PS of 178.27. The 5-year average PS is 83.90. The thresholds are as follows: Strongly Undervalued below -108.38, Undervalued between -108.38 and -12.24, Fairly Valued between 180.04 and -12.24, Overvalued between 180.04 and 276.18, and Strongly Overvalued above 276.18. The current Forward PS of 178.27 falls within the Historic Trend Line -Fairly Valued range.

-1.28

P/OCF

iBio Inc. (IBIO) has a current P/OCF of -1.28. The 5-year average P/OCF is -0.26. The thresholds are as follows: Strongly Undervalued below -2.29, Undervalued between -2.29 and -1.27, Fairly Valued between 0.75 and -1.27, Overvalued between 0.75 and 1.77, and Strongly Overvalued above 1.77. The current Forward P/OCF of -1.28 falls within the Undervalued range.

-0.65

P/FCF

iBio Inc. (IBIO) has a current P/FCF of -0.65. The 5-year average P/FCF is -0.13. The thresholds are as follows: Strongly Undervalued below -1.15, Undervalued between -1.15 and -0.64, Fairly Valued between 0.38 and -0.64, Overvalued between 0.38 and 0.89, and Strongly Overvalued above 0.89. The current Forward P/FCF of -0.65 falls within the Undervalued range.

iBio Inc (IBIO) has a current Price-to-Book (P/B) ratio of 0.63. Compared to its 3-year average P/B ratio of 0.86 , the current P/B ratio is approximately -26.81% higher. Relative to its 5-year average P/B ratio of 1.56, the current P/B ratio is about -59.75% higher. iBio Inc (IBIO) has a Forward Free Cash Flow (FCF) yield of approximately -132.61%. Compared to its 3-year average FCF yield of -285.65%, the current FCF yield is approximately -53.58% lower. Relative to its 5-year average FCF yield of -180.20% , the current FCF yield is about -26.41% lower.

0.63

P/B

Median3y

0.86

Median5y

1.56

-132.61

FCF Yield

Median3y

-285.65

Median5y

-180.20

Competitors Valuation Multiple

The average P/S ratio for IBIO's competitors is 29.82, providing a benchmark for relative valuation. iBio Inc Corp (IBIO) exhibits a P/S ratio of 178.27, which is 497.79% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PharmaCyte Biotech Inc

Loss

7.00M

QLGN.O

Qualigen Therapeutics Inc

Loss

4.12M

Performance Decomposition

Market capitalization of IBIO decreased by 66.35% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 0.00 to 0.00.

The secondary factor is the Margin Expansion, contributed -72.92%to the performance.

Overall, the performance of IBIO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 0.00

Revenue Growth

-72.92%

-24.39K → -6.61K

Margin Expansion

NaN%

NaN → -0.39

P/E Change

-66.35%